Shaoyuan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shaoyuan Zhang has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Lijie Tan
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
10 shared publications - Bianca Mostert
Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
3 shared publications - Charlène J. van der Zijden
Department of Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands
3 shared publications - Fredrik Klevebro
Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Surgery and Oncology, Karolinska Institutet, Stockholm, Sweden
3 shared publications - Jinjie Yu
Department of Thoracic Surgery, Zhongshan Hospital of Fudan University, Shanghai, People’s Republic of China
3 shared publications - Jun Okui
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX
3 shared publications
Latest Publications
- 16 October 2026
- Published by Springer Nature in Surgical Endoscopy
- p. 1-9
Thoracoscopic versus endoscopic resection for esophageal leiomyoma: a propensity score-matched retrospective cohort study
Introduction Esophageal leiomyoma is the most common benign mesenchymal tumor of the esophagus. Minimally invasive management is performed by thoracoscopic surgery or endoscopic resection, but comparative evidence remains limited. This study evaluated perioperative outcomes and treatment-selection patterns for thoracic and endoscopic resection. Methods Patients with pathologically confirmed leiomyoma who underwent resection between January 2015 and September 2023 were retrospectively reviewed. Patients with malignant components, biopsy/fine-needle aspiration only, or incomplete data were excluded. A 1:1 propensity score matching analysis was performed using nearest-neighbor matching with a caliper of 0.1, matching age, sex, tumor location, and maximal tumor diameter. Results A total of 1,348 patients were included in the primary analysis: 132 underwent minimally invasive thoracic surgery and 1,216 underwent endoscopic resection. In the endoscopic group, 54.5% underwent endoscopic submucosal dissection and 45.5% underwent submucosal tunneling endoscopic resection. In the MIS group, 62 patients (47.0%) received intraoperative endoscopic assistance. Endoscopic resection was associated with shorter operative duration (41.9 ± 39.9 vs 114.8 ± 71.0 min, p < 0.001) and shorter postoperative hospital stay (median 2.0 vs 5.0 days, p < 0.001), whereas minimally invasive thoracic surgery was used for larger tumors (median 5.0 vs 1.3 cm, p < 0.001). After matching, 113 pairs were analyzed. Endoscopic resection remained associated with shorter operative duration (73.7 ± 62.9 vs 111.6 ± 61.5 min, p = 0.009) and shorter postoperative hospital stay (median 3.0 vs 5.0 days, p < 0.001). In the matched cohort, nasogastric tube placement and delayed stay of 5 days or longer were less common after endoscopic resection. Conclusions Endoscopic resection was associated with faster postoperative recovery in patients with esophageal leiomyoma, whereas thoracic surgery remained important for larger tumors and complex lesions. These findings support a size- and location-oriented treatment strategy rather than a universal preference for either approach.
- 16 October 2026
- Published by Springer Nature in Surgical Endoscopy
- p. 1-9
Thoracoscopic versus endoscopic resection for esophageal leiomyoma: a propensity score-matched retrospective cohort study
Introduction Esophageal leiomyoma is the most common benign mesenchymal tumor of the esophagus. Minimally invasive management is performed by thoracoscopic surgery or endoscopic resection, but comparative evidence remains limited. This study evaluated perioperative outcomes and treatment-selection patterns for thoracic and endoscopic resection. Methods Patients with pathologically confirmed leiomyoma who underwent resection between January 2015 and September 2023 were retrospectively reviewed. Patients with malignant components, biopsy/fine-needle aspiration only, or incomplete data were excluded. A 1:1 propensity score matching analysis was performed using nearest-neighbor matching with a caliper of 0.1, matching age, sex, tumor location, and maximal tumor diameter. Results A total of 1,348 patients were included in the primary analysis: 132 underwent minimally invasive thoracic surgery and 1,216 underwent endoscopic resection. In the endoscopic group, 54.5% underwent endoscopic submucosal dissection and 45.5% underwent submucosal tunneling endoscopic resection. In the MIS group, 62 patients (47.0%) received intraoperative endoscopic assistance. Endoscopic resection was associated with shorter operative duration (41.9 ± 39.9 vs 114.8 ± 71.0 min, p < 0.001) and shorter postoperative hospital stay (median 2.0 vs 5.0 days, p < 0.001), whereas minimally invasive thoracic surgery was used for larger tumors (median 5.0 vs 1.3 cm, p < 0.001). After matching, 113 pairs were analyzed. Endoscopic resection remained associated with shorter operative duration (73.7 ± 62.9 vs 111.6 ± 61.5 min, p = 0.009) and shorter postoperative hospital stay (median 3.0 vs 5.0 days, p < 0.001). In the matched cohort, nasogastric tube placement and delayed stay of 5 days or longer were less common after endoscopic resection. Conclusions Endoscopic resection was associated with faster postoperative recovery in patients with esophageal leiomyoma, whereas thoracic surgery remained important for larger tumors and complex lesions. These findings support a size- and location-oriented treatment strategy rather than a universal preference for either approach.
- Top Cited PapersOpen Access
- 17 February 2026
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 113 (3)
Survival after pathological complete response following neoadjuvant chemotherapy versus chemoradiotherapy for oesophageal squamous cell carcinoma
Background: Although several oesophageal squamous cell carcinoma (OSCC) studies have reported no definitive overall survival (OS) differences between neoadjuvant chemoradiotherapy (NACRT) and neoadjuvant chemotherapy (NAC), the higher pCR rate with NACRT has been viewed as a potential advantage. Beyond ongoing concerns about the validity of pCR as a surrogate endpoint, it remains uncertain whether survival differs between these modalities among patients with OSCC who achieve pCR. Methods: An integrated analysis of individual patient data (IPD) from phase III trials evaluating perioperative therapies for resectable OSCC was conducted, emphasizing prognostic differences between NAC and NACRT, particularly among patients who achieved pCR. Results: IPD from seven phase III RCTs across six countries included data for 1044 patients with OSCC (83.5% male; mean age of 62.3 years). Of these patients, 605 (58.0%) received NAC and 439 (42.0%) received NACRT, with R0 resection rates of 89.6% versus 84.7% and pCR rates of 6.9% versus 34.2% respectively. Among patients who achieved pCR (192 patients), 5-year OS was 97.5% in the NAC group and 70.4% in the NACRT group, while 5-year recurrence-free survival was 80.8% and 63.7% respectively. Multivariable analysis demonstrated a significant survival advantage for NAC among patients who achieved pCR. Conclusion: Among patients who achieved pCR, postoperative outcomes varied considerably by neoadjuvant treatment modality. The markedly favourable prognosis associated with pCR after NAC suggests that these patients may represent an optimal candidate cohort for future evaluation of surgery-avoidance and watch-and-wait strategies.
- 17 February 2026
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 113 (3)
Top Cited PapersOpen AccessSurvival after pathological complete response following neoadjuvant chemotherapy versus chemoradiotherapy for oesophageal squamous cell carcinoma
Background: Although several oesophageal squamous cell carcinoma (OSCC) studies have reported no definitive overall survival (OS) differences between neoadjuvant chemoradiotherapy (NACRT) and neoadjuvant chemotherapy (NAC), the higher pCR rate with NACRT has been viewed as a potential advantage. Beyond ongoing concerns about the validity of pCR as a surrogate endpoint, it remains uncertain whether survival differs between these modalities among patients with OSCC who achieve pCR. Methods: An integrated analysis of individual patient data (IPD) from phase III trials evaluating perioperative therapies for resectable OSCC was conducted, emphasizing prognostic differences between NAC and NACRT, particularly among patients who achieved pCR. Results: IPD from seven phase III RCTs across six countries included data for 1044 patients with OSCC (83.5% male; mean age of 62.3 years). Of these patients, 605 (58.0%) received NAC and 439 (42.0%) received NACRT, with R0 resection rates of 89.6% versus 84.7% and pCR rates of 6.9% versus 34.2% respectively. Among patients who achieved pCR (192 patients), 5-year OS was 97.5% in the NAC group and 70.4% in the NACRT group, while 5-year recurrence-free survival was 80.8% and 63.7% respectively. Multivariable analysis demonstrated a significant survival advantage for NAC among patients who achieved pCR. Conclusion: Among patients who achieved pCR, postoperative outcomes varied considerably by neoadjuvant treatment modality. The markedly favourable prognosis associated with pCR after NAC suggests that these patients may represent an optimal candidate cohort for future evaluation of surgery-avoidance and watch-and-wait strategies.
- 23 January 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (5) , 617-631
C-type lectin-like receptor 2 in lung epithelium protects against acute lung injury
C-type lectin-like receptor 2 (CLEC2) is a transmembrane receptor highly expressed on platelets, which regulates platelet aggregation and immune response. Yet, the function of CLEC2 in lung epithelium and its contribution to acute lung injury (ALI) is unclear. In this study, a lung epithelial–specific CLEC2 knockout mouse (Clec1bAT2-KO) was generated and performed for ALI models. In both LPS- and acid-induced lung injury models, the ALI signs of Clec1bAT2-KO mice were further exacerbated. The therapeutic application of epithelial-restricted CLEC2 overexpression using adeno-associated virus (AAV) or CLEC2 activation using its endogenous ligand podoplanin serves as a lung epithelial protective agent in the setting of ALI. Transcriptomic analyses reveal that CLEC2-regulated genes are highly enriched in chemotaxis, cytokine, and extracellular matrix (ECM) components. Lung injury was partially attenuated in Ccl5−/−, Csf3−/−, and Cxcl1−/− mice pretreated with AAV-si-CLEC2, followed by LPS challenge. Loss of CLEC2 leads to ECM degradation, which could be reversed by exogenous transforming growth factor beta (TGF-β). Furthermore, interferon regulatory factor 1 (IRF1) was identified as the key molecule that regulates CLEC2-related cytokine/chemokine production and ECM degradation. These findings suggest that epithelial CLEC2 protects against ALI by modulating spleen tyrosine kinase/IRF1-mediated cytokine/chemokine production and TGF-β–mediated ECM remodeling.
- 23 January 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (5) , 617-631
C-type lectin-like receptor 2 in lung epithelium protects against acute lung injury
C-type lectin-like receptor 2 (CLEC2) is a transmembrane receptor highly expressed on platelets, which regulates platelet aggregation and immune response. Yet, the function of CLEC2 in lung epithelium and its contribution to acute lung injury (ALI) is unclear. In this study, a lung epithelial–specific CLEC2 knockout mouse (Clec1bAT2-KO) was generated and performed for ALI models. In both LPS- and acid-induced lung injury models, the ALI signs of Clec1bAT2-KO mice were further exacerbated. The therapeutic application of epithelial-restricted CLEC2 overexpression using adeno-associated virus (AAV) or CLEC2 activation using its endogenous ligand podoplanin serves as a lung epithelial protective agent in the setting of ALI. Transcriptomic analyses reveal that CLEC2-regulated genes are highly enriched in chemotaxis, cytokine, and extracellular matrix (ECM) components. Lung injury was partially attenuated in Ccl5−/−, Csf3−/−, and Cxcl1−/− mice pretreated with AAV-si-CLEC2, followed by LPS challenge. Loss of CLEC2 leads to ECM degradation, which could be reversed by exogenous transforming growth factor beta (TGF-β). Furthermore, interferon regulatory factor 1 (IRF1) was identified as the key molecule that regulates CLEC2-related cytokine/chemokine production and ECM degradation. These findings suggest that epithelial CLEC2 protects against ALI by modulating spleen tyrosine kinase/IRF1-mediated cytokine/chemokine production and TGF-β–mediated ECM remodeling.
- Open Access
- 8 January 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (4) , 737-745
Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials
Background: Most recurrences after curative surgery for esophageal cancer occur within 2 years. Conventional recurrence-free survival (RFS), calculated from the time of surgery, may underestimate prognosis for patients who remain recurrence-free during the early postoperative years. This study aimed to evaluate conditional RFS and recurrence timing to inform individualized follow-up strategies. Methods: An individual patient data (IPD) analysis was conducted using randomized controlled trials (RCTs) comparing perioperative treatments for resectable esophageal or gastroesophageal junction cancer. Conditional RFS, defined as the probability of remaining recurrence-free for an additional y years given x years already survived without recurrence (RFSy|RFSx), was estimated. Results: IPD from 10 phase III and 1 phase II RCTs were analyzed (n = 2268 patients with R0 resection). In squamous cell carcinoma (SCC), RFS5|RFS0 was 47.9%, which increased to 63.0%, 72.5%, 78.2%, and 81.2% at RFS5|RFS1–4. Among patients who recurred, 58.8% of pN-positive cases recurred within 1 year and 81.7% within 2 years, compared with 42.8% and 69.9% in pN0. At baseline (RFS5|RFS0), patients with pN-positive disease or pM1 disease had worse 5-year RFS than those with pN0 or pM0 disease. However, among patients who remained recurrence-free for 4 years after surgery (RFS5|RFS4), the pattern was reversed, with advanced groups showing better subsequent 5-year RFS. Similar trends were observed in adenocarcinoma. Conclusions: Conditional RFS improves over time, particularly in advanced-stage esophageal cancer. Although advanced cases are typically monitored more intensively, findings suggest comparable follow-up intensity may be appropriate once patients remain recurrence-free for a certain postoperative period.
- 8 January 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (4) , 737-745
Open AccessConditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials
Background: Most recurrences after curative surgery for esophageal cancer occur within 2 years. Conventional recurrence-free survival (RFS), calculated from the time of surgery, may underestimate prognosis for patients who remain recurrence-free during the early postoperative years. This study aimed to evaluate conditional RFS and recurrence timing to inform individualized follow-up strategies. Methods: An individual patient data (IPD) analysis was conducted using randomized controlled trials (RCTs) comparing perioperative treatments for resectable esophageal or gastroesophageal junction cancer. Conditional RFS, defined as the probability of remaining recurrence-free for an additional y years given x years already survived without recurrence (RFSy|RFSx), was estimated. Results: IPD from 10 phase III and 1 phase II RCTs were analyzed (n = 2268 patients with R0 resection). In squamous cell carcinoma (SCC), RFS5|RFS0 was 47.9%, which increased to 63.0%, 72.5%, 78.2%, and 81.2% at RFS5|RFS1–4. Among patients who recurred, 58.8% of pN-positive cases recurred within 1 year and 81.7% within 2 years, compared with 42.8% and 69.9% in pN0. At baseline (RFS5|RFS0), patients with pN-positive disease or pM1 disease had worse 5-year RFS than those with pN0 or pM0 disease. However, among patients who remained recurrence-free for 4 years after surgery (RFS5|RFS4), the pattern was reversed, with advanced groups showing better subsequent 5-year RFS. Similar trends were observed in adenocarcinoma. Conclusions: Conditional RFS improves over time, particularly in advanced-stage esophageal cancer. Although advanced cases are typically monitored more intensively, findings suggest comparable follow-up intensity may be appropriate once patients remain recurrence-free for a certain postoperative period.
- 25 September 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (3) , 350-363
Ex vivo lung perfusion enhances donor lung preservation in mice via Hippo signaling activation
Rationale: Ex vivo lung perfusion (EVLP) is a promising technique that allows organ preservation and repair, while the molecular mechanisms remain unknown. Objectives: This study aimed to establish a translational murine EVLP model and to unveil the molecular mechanisms responsible for EVLP beneficial effects. Methods: We developed a murine EVLP system with four experimental groups: (1) without ischemia or EVLP (control), (2) 45 minutes of EVLP followed by 135 minutes cold ischemia (EVLP-CI), (3) 135 minutes of cold ischemia (CI) followed by 45 minutes of EVLP (CI-EVLP), and (4) 180 minutes of CI. Following 3-hour preservation, changes in lung weight (Δweight) and lung vascular filtration coefficient (Kf) were measured. Complementary in vitro studies utilized human pulmonary microvascular endothelial cells (hPMVECs) under simulated perfusion conditions. Measurements and Main Results: Compared with the CI group, both EVLP intervention groups exhibited superior preservation outcomes, with an attenuated Δweight and Kf, and histological and microscopic evidence of lung damage. Proteomic profiling on mouse lungs revealed that EVLP regulated the Hippo signaling in response to CI. Pharmacological inhibition or genetic deletion of Yap1 or Lats1 specifically in endothelial cells (Yap1EN-KO or Lats1EN-KO) abrogated EVLP-mediated endothelial barrier protection. EVLP efficacy in lung preservation was enhanced by Yap1 phosphorylation activation using AICAR or metformin. In vitro perfusion models recapitulated these findings, where barrier function was disrupted with Yap1 phosphorylation inhibitor, with a decreased cytoplasmic localization of Yap1. Conclusions: Our findings establish the functional murine EVLP model and first demonstrate that mechanical perfusion preserves donor lung viability through Hippo signaling-mediated endothelial barrier stabilization.
- 25 September 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (3) , 350-363
Ex vivo lung perfusion enhances donor lung preservation in mice via Hippo signaling activation
Rationale: Ex vivo lung perfusion (EVLP) is a promising technique that allows organ preservation and repair, while the molecular mechanisms remain unknown. Objectives: This study aimed to establish a translational murine EVLP model and to unveil the molecular mechanisms responsible for EVLP beneficial effects. Methods: We developed a murine EVLP system with four experimental groups: (1) without ischemia or EVLP (control), (2) 45 minutes of EVLP followed by 135 minutes cold ischemia (EVLP-CI), (3) 135 minutes of cold ischemia (CI) followed by 45 minutes of EVLP (CI-EVLP), and (4) 180 minutes of CI. Following 3-hour preservation, changes in lung weight (Δweight) and lung vascular filtration coefficient (Kf) were measured. Complementary in vitro studies utilized human pulmonary microvascular endothelial cells (hPMVECs) under simulated perfusion conditions. Measurements and Main Results: Compared with the CI group, both EVLP intervention groups exhibited superior preservation outcomes, with an attenuated Δweight and Kf, and histological and microscopic evidence of lung damage. Proteomic profiling on mouse lungs revealed that EVLP regulated the Hippo signaling in response to CI. Pharmacological inhibition or genetic deletion of Yap1 or Lats1 specifically in endothelial cells (Yap1EN-KO or Lats1EN-KO) abrogated EVLP-mediated endothelial barrier protection. EVLP efficacy in lung preservation was enhanced by Yap1 phosphorylation activation using AICAR or metformin. In vitro perfusion models recapitulated these findings, where barrier function was disrupted with Yap1 phosphorylation inhibitor, with a decreased cytoplasmic localization of Yap1. Conclusions: Our findings establish the functional murine EVLP model and first demonstrate that mechanical perfusion preserves donor lung viability through Hippo signaling-mediated endothelial barrier stabilization.
- Open Access
- 31 May 2025
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 112 (6)
Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable oesophageal cancer: integrated analysis of individual patient data from phase III trials
Background: Overall survival (OS) is the standard endpoint for oncological treatment efficacy, but requires long follow-up. The aim of this study was to evaluate pCR as a surrogate for OS in oesophageal cancer. Methods: An integrated analysis of individual patient data (IPD) from phase III trials comparing perioperative therapies for resectable oesophageal and gastro-oesophageal junction cancer was conducted. Individual-level surrogacy between pCR and OS was assessed using Kendall’s rank correlation coefficient (τ). A τ of 0.8 was considered a threshold for a good surrogate. As no method estimating τ between an ordinal endpoint and OS has been reported, a new method was proposed using the inverse-probability-of-censoring weighted estimator adjusted for tied data. Results: Of 22 eligible trials, 10 provided IPD for 1641 patients, including 624 who received neoadjuvant chemotherapy (NAC; 45 (7.2%) achieved pCR) and 1017 who received neoadjuvant chemoradiotherapy (NACRT; 299 (29.4%) achieved pCR). In the NAC subgroup, patients with pCR had an HR for OS of 0.12 (95% c.i. 0.05 to 0.33), the C-index was 0.54 (95% c.i. 0.52 to 0.56), and τ was 0.256. In the NACRT subgroup, the HR was 0.57 (95% c.i. 0.47 to 0.70), the C-index was 0.56 (95% c.i. 0.54 to 0.58), and τ was 0.174. Hypothetical data suggested that achieving strong surrogacy (τ of 0.8) required an HR of 0.09 (95% c.i. 0.07 to 0.11). Conclusion: Although pCR was correlated with OS, no evidence of individual-level surrogacy with OS was demonstrated, making it inappropriate to consider pCR as a surrogate endpoint for OS in resectable oesophageal cancer.
- 31 May 2025
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 112 (6)
Open AccessEvaluation of pathological complete response as a surrogate endpoint for overall survival in resectable oesophageal cancer: integrated analysis of individual patient data from phase III trials
Background: Overall survival (OS) is the standard endpoint for oncological treatment efficacy, but requires long follow-up. The aim of this study was to evaluate pCR as a surrogate for OS in oesophageal cancer. Methods: An integrated analysis of individual patient data (IPD) from phase III trials comparing perioperative therapies for resectable oesophageal and gastro-oesophageal junction cancer was conducted. Individual-level surrogacy between pCR and OS was assessed using Kendall’s rank correlation coefficient (τ). A τ of 0.8 was considered a threshold for a good surrogate. As no method estimating τ between an ordinal endpoint and OS has been reported, a new method was proposed using the inverse-probability-of-censoring weighted estimator adjusted for tied data. Results: Of 22 eligible trials, 10 provided IPD for 1641 patients, including 624 who received neoadjuvant chemotherapy (NAC; 45 (7.2%) achieved pCR) and 1017 who received neoadjuvant chemoradiotherapy (NACRT; 299 (29.4%) achieved pCR). In the NAC subgroup, patients with pCR had an HR for OS of 0.12 (95% c.i. 0.05 to 0.33), the C-index was 0.54 (95% c.i. 0.52 to 0.56), and τ was 0.256. In the NACRT subgroup, the HR was 0.57 (95% c.i. 0.47 to 0.70), the C-index was 0.56 (95% c.i. 0.54 to 0.58), and τ was 0.174. Hypothetical data suggested that achieving strong surrogacy (τ of 0.8) required an HR of 0.09 (95% c.i. 0.07 to 0.11). Conclusion: Although pCR was correlated with OS, no evidence of individual-level surrogacy with OS was demonstrated, making it inappropriate to consider pCR as a surrogate endpoint for OS in resectable oesophageal cancer.
- Open Access
- 22 January 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (1) , 27047
SUMO-Specific Peptidase 5 Promotes Oesophageal Squamous Cell Carcinoma Growth through the NF-κB-SLC1A3 Axis
Background: This study investigates the role of small ubiquitin-like modifier (SUMO)-specific peptidase 5 (SENP5), a key regulator of SUMOylation, in esophageal squamous cell carcinoma (ESCC), a lethal disease, and its underlying molecular mechanisms. Methods: Differentially expressed genes between ESCC mouse oesophageal cancer tissues and normal tissues were analysed via RNA-seq; among them, SENP5 expression was upregulated, and this gene was selected for further analysis. Immunohistochemistry and western blotting were then used to validate the increased protein level of SENP5 in both mouse and human ESCC samples. The Kaplan‒Meier method and multivariate analysis were used to analyse the relationship between SENP5 expression and ESCC prognosis. Stable SENP5-knockdown (KD) cell lines and conditional knockout (cKO) mice were established to verify the biological function of SENP5. Further RNA-seq comparisons between short hairpin SENP5 (shSENP5)- and short hairpin negative control (shNC)-transfected ESCC cell lines were conducted, and the nuclear factor kappa B (NF-κB)—SLC1A3 axis was identified through bioinformatics analysis. The correlation of SENP5 with signalling pathway components was validated via real-time quantitative PCR (qPCR), western blotting (WB), and immunoprecipitation. Results: Our study revealed that SENP5 was upregulated in human and mouse ESCC samples, and clinical data analysis revealed a correlation between high SENP5 expression and poor patient prognosis. SENP5 knockdown inhibited tumorigenesis and growth in vivo and suppressed the proliferation, migration, and invasion of ESCC cell lines in vitro. Our study also revealed that SENP5 knockdown enhanced the SUMO1-mediated SUMOylation of NF-kappa-B inhibitor alpha (IκBα), thereby inhibiting the activation of the NF-κB–SLC1A3 axis, which subsequently suppresses ESCC cell energy metabolism and impedes ESCC progression. Conclusions: Suppression of SENP5 slows the development of ESCC by inhibiting the NF-κB‒SLC1A3 axis through SUMO1-mediated SUMOylation of IκBα. Our research suggests that SENP5 could serve as a prognostic indicator and a target for therapeutic intervention for ESCC patients.
- 22 January 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (1) , 27047
Open AccessSUMO-Specific Peptidase 5 Promotes Oesophageal Squamous Cell Carcinoma Growth through the NF-κB-SLC1A3 Axis
Background: This study investigates the role of small ubiquitin-like modifier (SUMO)-specific peptidase 5 (SENP5), a key regulator of SUMOylation, in esophageal squamous cell carcinoma (ESCC), a lethal disease, and its underlying molecular mechanisms. Methods: Differentially expressed genes between ESCC mouse oesophageal cancer tissues and normal tissues were analysed via RNA-seq; among them, SENP5 expression was upregulated, and this gene was selected for further analysis. Immunohistochemistry and western blotting were then used to validate the increased protein level of SENP5 in both mouse and human ESCC samples. The Kaplan‒Meier method and multivariate analysis were used to analyse the relationship between SENP5 expression and ESCC prognosis. Stable SENP5-knockdown (KD) cell lines and conditional knockout (cKO) mice were established to verify the biological function of SENP5. Further RNA-seq comparisons between short hairpin SENP5 (shSENP5)- and short hairpin negative control (shNC)-transfected ESCC cell lines were conducted, and the nuclear factor kappa B (NF-κB)—SLC1A3 axis was identified through bioinformatics analysis. The correlation of SENP5 with signalling pathway components was validated via real-time quantitative PCR (qPCR), western blotting (WB), and immunoprecipitation. Results: Our study revealed that SENP5 was upregulated in human and mouse ESCC samples, and clinical data analysis revealed a correlation between high SENP5 expression and poor patient prognosis. SENP5 knockdown inhibited tumorigenesis and growth in vivo and suppressed the proliferation, migration, and invasion of ESCC cell lines in vitro. Our study also revealed that SENP5 knockdown enhanced the SUMO1-mediated SUMOylation of NF-kappa-B inhibitor alpha (IκBα), thereby inhibiting the activation of the NF-κB–SLC1A3 axis, which subsequently suppresses ESCC cell energy metabolism and impedes ESCC progression. Conclusions: Suppression of SENP5 slows the development of ESCC by inhibiting the NF-κB‒SLC1A3 axis through SUMO1-mediated SUMOylation of IκBα. Our research suggests that SENP5 could serve as a prognostic indicator and a target for therapeutic intervention for ESCC patients.
- Open Access
SENP2 promotes ESCC proliferation through SETDB1 deSUMOylation and enhanced fatty acid metabolism
- Top Cited Papers
- 27 June 2024
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 169 (1) , 289-300.e6
Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma
- 27 June 2024
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 169 (1) , 289-300.e6
Top Cited PapersPerioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma
- 16 September 2023
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 50 (12) , 964-972
Telocytes protect against lung tissue fibrosis through hexokinase 2‐dependent pathway by secreting hepatocyte growth factor
Pulmonary fibrosis (PF) is one of the common manifestations of end‐stage lung disease. Chronic lung failure after lung transplantation is mainly caused by bronchiolitis obliterans syndrome (BOS) and is mainly characterized by lung tissue fibrosis. Pulmonary epithelial‐mesenchymal transformation (EMT) is crucial for pulmonary fibrosis. Telocytes (TCs), a new type of mesenchymal cells, play a protective role in various acute injuries. For exploring the anti‐pulmonary fibrosis effect of TCs in the BOS model in vitro and the related mechanism, rat tracheal epithelial (RTE) cells were treated with transforming growth factor‐β (TGF‐β) to simulate lung tissue fibrosis in vitro. The RTE cells were then co‐cultured with TCs primarily extracted from rat lung tissue. Western blot, Seahorse XF Analysers and enzyme‐linked immunosorbent assay were used to detect the level of EMT and aerobic respiration of RTE cells. Furthermore, anti‐hepatocyte growth factor (anti‐HGF) antibody was exogenously added to the cultured cells to explore further mechanisms. Moreover, hexokinase 2 (HK2) in RTE cells was knocked down to assess whether it influences the blocking effect of the anti‐HGF antibody. TGF‐β could induce lung tissue fibrosis in RTE cells in vitro. Nevertheless, TCs co‐culture decreased the level of EMT, glucose metabolic indicators (lactate and ATP) and oxygen levels. Furthermore, TCs released hepatocyte growth factor (HGF). Therefore, the exogenous addition of anti‐HGF antibody in the co‐culture system blocked the anti‐lung tissue fibrosis effect. However, HK2 knockdown attenuated the blocking effect of the anti‐HGF antibody. In conclusion, TCs can protect against lung tissue fibrosis by releasing HGF, a process dependent on HK2.
- 16 September 2023
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 50 (12) , 964-972
Telocytes protect against lung tissue fibrosis through hexokinase 2‐dependent pathway by secreting hepatocyte growth factor
Pulmonary fibrosis (PF) is one of the common manifestations of end‐stage lung disease. Chronic lung failure after lung transplantation is mainly caused by bronchiolitis obliterans syndrome (BOS) and is mainly characterized by lung tissue fibrosis. Pulmonary epithelial‐mesenchymal transformation (EMT) is crucial for pulmonary fibrosis. Telocytes (TCs), a new type of mesenchymal cells, play a protective role in various acute injuries. For exploring the anti‐pulmonary fibrosis effect of TCs in the BOS model in vitro and the related mechanism, rat tracheal epithelial (RTE) cells were treated with transforming growth factor‐β (TGF‐β) to simulate lung tissue fibrosis in vitro. The RTE cells were then co‐cultured with TCs primarily extracted from rat lung tissue. Western blot, Seahorse XF Analysers and enzyme‐linked immunosorbent assay were used to detect the level of EMT and aerobic respiration of RTE cells. Furthermore, anti‐hepatocyte growth factor (anti‐HGF) antibody was exogenously added to the cultured cells to explore further mechanisms. Moreover, hexokinase 2 (HK2) in RTE cells was knocked down to assess whether it influences the blocking effect of the anti‐HGF antibody. TGF‐β could induce lung tissue fibrosis in RTE cells in vitro. Nevertheless, TCs co‐culture decreased the level of EMT, glucose metabolic indicators (lactate and ATP) and oxygen levels. Furthermore, TCs released hepatocyte growth factor (HGF). Therefore, the exogenous addition of anti‐HGF antibody in the co‐culture system blocked the anti‐lung tissue fibrosis effect. However, HK2 knockdown attenuated the blocking effect of the anti‐HGF antibody. In conclusion, TCs can protect against lung tissue fibrosis by releasing HGF, a process dependent on HK2.